Pregnancy is a complex process that can be jeopardized when associated with cancer, because of the coexistence of two complex metabolic conditions: a fetus and cancer. The aim of this study was to evaluate fetal growth in association with cancer development as well as the indirect effects produced by tumors in pregnant mice subjected to a leucine-rich diet, knowing that leucine supplementation can minimize the tumor effects by acting as a cell signaling agent to improve the protein synthesis process. We evaluated fetuses (n ¼ 6) from NMRI pregnant mice fed either a control or a leucine-rich diet in either the presence or absence of an MAC16 colon adenocarcinoma or ascitic fluid inoculation. The fetal serum amino acids were separated using high-performance liquid chromatography, and fetal cytokine levels were analyzed using a microsphere-based multiplex immunoassay (Luminex xMAP). Fetal body composition was measured as the water, fat, and protein total content and total serum protein, albumin, and glucose content. Tumor growth resulted in a severe reduction in fetal body weight and protein content and increased fetal resorption, associated with placental weight decrease; these effects were minimized by a leucine-rich diet. Serum total protein and glucose content were reduced in fetuses from tumor-bearing dams but were reverted by nutritional supplementation. The serum amino acid profiles differed significantly between the tumor-bearing mice fed with a leucine-rich diet and controls. Certain tumor effects were reproduced in fetuses from ascitic fluid-injected dams, suggesting indirect effects of tumor growth. We conclude that certain effects of tumor growth can be mimicked by ascitic fluid injection and can be modulated by a leucine-rich diet.
INTRODUCTION
Pregnancy is a complex process involving a series of physiological steps, and certain clinical complications can modify the homeostasis adjustments during this process. The incidence of cancer during pregnancy is low, but the pregnancy complications are particularly serious, because of the coexistence of two complex metabolic conditions: the fetus and the cancer [1, 2] . In a tumor-bearing mother, there is possible nutritional competition between the fetus and the tumor, resulting in impaired growth and metabolic changes in both the mother and the fetus [3] [4] [5] . However, in previous work, the fetal and placental damage noted during tumor evolution was due not only to nutritional competition but also to indirect effects due to substances synthesized by the tumor and/or host cells [2, [6] [7] [8] . In our previous work, we isolated a proteolysisinducing factor from the ascitic fluid of Walker tumor-bearing rats [9] , which induced fetal resorption in pregnant rats [10] . Likewise, cancer induces a variety of host metabolic disorders such as alterations in the amino acid profile. The amino acid profile in cancer patients often differs from that in healthy individuals [11] because amino acids are essential for protein formation, and they can act in many metabolic networks [12] [13] [14] [15] [16] [17] . Tumor cells use substrates such as alanine, glutamine, lactic acid, and ketone bodies as structural or energetic sources [18] . Certain specific amino acids, such as leucine, can also initiate cell signaling pathways and stimulate PI3K/Akt/mTOR [19] . Dietary and nutrient supplementation can minimize the damage caused by a tumor, such as high mobilization of host proteins with a decrease in lean body mass and body fat depletion [20] . In previous work, we found that leucine acts as a cell signal to improve the protein synthesis process and inhibits proteolysis in tumor-bearing animals [21] [22] [23] [24] [25] . As previously reported by Argilés and López-Soriano [26] , leucine oxidation is increased in tumor-bearing animals. This finding supports the high demand of both skeletal muscle and tumor tissue, which appears to contribute to the enhanced amino acid turnover. Based on this beneficial effect produced by leucine, the aim of this study was to investigate whether tumor evolution competes as a nutritional factor jeopardizing fetal growth and how the leucine supplementation can modulate this damage effect. Therefore, we investigated the direct or indirect tumor effects by ascitic fluid injection, and also the leucine modulatory effect, on the fetal serum amino acid and cytokine profiles and the body composition of fetuses from pregnant, tumor-bearing mice.
MATERIALS AND METHODS

Reagents
Biochemical reagents were purchased from Labsynth (Diadema, São Paulo, Brasil), Merck KgaA (Darmstadt, Germany), Millipore Corporation (Jaffrey, NH), Promega (Madison, WI), Riedel-de Haën (Hanover, Germany), and Sigma Chemical Company (St. Louis, MO).
Animals and Diets
Forty-eight female NMRI mice (approximately 60-90 days of age) were obtained from the animal facilities of the State University of Campinas (Campinas, São Paulo, Brazil). The females were mated with adult males overnight (4:1 female-male ratio) as described by the harem method [27] . The first day of pregnancy was determined based on a vaginal smear. All pregnant mice were maintained in collective cages, with free access to water and food under standard conditions (228C 6 28C, 12L:12D cycle).
The semipurified diets were in accordance with AIN-93 from the American Institute of Nutrition [28] . The normo-protein diet (C) contained 18% protein (with casein as the sole source of protein) [28] ; the leucine-rich diet (L) contained 18% protein and 3% L-leucine (Table 1 ) [24] . The diets contained similar amounts of nitrogen (approximately 13.2 mg N 2 /100 g diet) [29] . The caloric adjustment of the amino acid-rich diet was accomplished by reducing the equivalent amount of carbohydrates that corresponded to isocaloric diets. The other ingredients contained the same amount of fat, fiber, salt and vitamin mix, and cysteine and choline as the normo-protein diet.
Tumor Implants and Ascitic Fluid Injections
The MAC16 colon adenocarcinoma, originally donated by Professor Michael J. Tisdale (Aston University, Birmingham, England), was stored in our laboratory under liquid nitrogen and maintained through consecutive s.c. or i.p. passages. The mice assigned to the tumor-bearing groups MAC and LMAC received an s.c. injection of MAC16 tumor cells (approximately 1 3 10 6 viable cells in 0.2 ml of saline solution) in the right flank after pregnancy confirmation. The ascitic fluid obtained from the peritoneal cavity of MAC16-tumor-bearing mice was centrifuged at 500 3 g for 10 min to remove the neoplastic cells. This fluid was then injected (i.p.) into the pregnant, nontumor-bearing mice, which were assigned to the ascitic fluid-injected groups A and LA, to investigate the indirect effect of tumor MAC16, as the ascitic fluid contains cytokines and especially proteolysis-inducing factor [30] . Groups A and LA received i.p. injections daily with 0.2 ml of ascitic fluid until the 19th day of pregnancy. All groups were monitored through 19 days of pregnancy, which corresponded to 17 days after tumor implantation. Sham groups were injected daily with 0.2 ml NaCl (0.9%) during those 17 days, and no difference was found when compared to control groups (data not shown). The general UKCCCR [31] guidelines for animal welfare were followed, and the protocols were approved by the Institutional Committee for Ethics in Animal Research (CEEA/IB/UNICAMP, protocol 1925-1).
Experimental Procedures
The pregnant mice received either tumor implants on the second day of pregnancy or ascitic fluid injection from the fifth day (corresponding to when the tumor became palpable) to the 19th day of pregnancy. On Day 19, one fetus was randomly chosen and collected from each dam (n ¼ 6 animals per group). Three groups were fed with a control diet: C indicates the pregnant control; MAC indicates a tumor-bearing, pregnant animal fed a control diet; and A indicates a pregnant animal injected with ascitic fluid and fed a control diet. Three other groups were fed with a leucine-rich diet: L indicates a pregnant animal fed the leucine-rich diet; LMAC indicates a tumor-bearing, pregnant animal fed the leucine-rich diet; and LA indicates a pregnant animal injected with ascitic fluid and fed the leucine-rich diet.
The pregnant mice were euthanized through cervical dislocation on the 19 th day of pregnancy. The fetuses were weighed, and serum was collected for analysis of the serum amino acid profile and the serum total protein, albumin, and glucose content. The fetal muscle was assessed for the total protein content and the phenylalanine and tyrosine content. The fetal carcasses were dehydrated to assay the chemical body composition for water, total body fat, and protein content.
Biochemical Analyses
The fetal serum was analyzed to determine the total protein, albumin, and glucose content. The serum total protein content was determined using Biuret reactive materials, and the reaction was read at an absorbance of 540 nm, in accordance with Doumas et al. [32] . The albumin levels were determined using the fetal serum in combination with bromocresol green. This reaction was read at 630 nm absorbance, in accordance with Doumas et al. [32] . The glucose levels were measured using the glucose-oxidase reactive materials, and the reaction was read at 540 nm absorbance, in accordance with Trinder [33] . The serum cytokine (IL-1, IL-6, TNF, IFN, IL-10, and IL-4) profile was measured using a specific kit (rat cytokine immunoassay, catalog RCYRO-80K-06) from Millipore and a Luminex 200 (Luminex Corporation, Austin, TX) following the manufacturer's technical procedures.
The fetal chemical body composition was analyzed using the method described by Salomão and Gomes-Marcondes [25] . The fetuses were dehydrated until a constant weight was observed at 508C to measure the total body water content. Then, the total fat was removed using petrol ether extraction, and the weight difference between the dry carcass and the carcass without fat was used to determine the fetal fat mass. The carcass total protein content was determined using a colorimetric method with the Folin-Ciocalteu reagent as described by Lowry et al. [34] .
The fetal muscle tyrosine was measured using a fluorometric assay as described by Waalkes and Udenfriend [35] .
Amino Acid Measurements
The concentration of amino acids in the fetal serum and muscle was analyzed after sample deproteination with 20 ll of sulfosalicylic acid, and the supernatant was assessed using high-performance liquid chromatography. Amino acids were isolated according to the separation protocol developed by Bidlingmeyer et al. [36] . The separation column was a C18 Waters PicoÁTag (Waters Corporation, Milford, MA), 3.9 3 150 mm. The chromatography was developed at a constant temperature of 38.08C 6 0.18C on the CM4000 Laboratory Data Control machine (Milton Roy Co., Ivyland, PA). The data were collected using the computer software ThermoChrom III Thermo Separation Products (ThermoChrom software 1.0, Media Cybernetics, Inc., Rockville, MD). The quantification of PTC-aa had a coefficient of variation between duplicates 10% (criterion reliable method). The dose-response pattern had a linear relationship between the peak area and the amount of amino acid derivatives in the range of 25-2500 pmol of each amino acid.
Statistical Analyses
The data are expressed as the mean 6 SD. The data were analyzed statistically by a two-way ANOVA (Graph Pad Prism software, version 3.00 for Windows 98; GraphPad Software, San Diego, CA) testing the effects of diet, tumor, and ascitic fluid on fetal (serum profile and body chemical composition) and placental parameters. Comparison within control and tumorbearing groups was performed using one-way ANOVA following by post-hoc Bonferroni multiple-comparison test. The results were considered significant when P , 0.05 [37] .
RESULTS
The Maternal MAC16 Tumor Effects on Fetal Growth
The fetal body weight was reduced by approximately 18% in the MAC and A groups (Table 2) , and there was an increase in fetal resorption in the MAC groups. In addition, there was a smaller amount of fetal resorption (approximately 50% less) when the dams were supplemented with a leucine rich-diet (MAC ¼ 3.2 6 0.2 vs. LMAC ¼ 1.7 6 0.3, Table 2 ). These data show that diet accounted for 40% of the total variance, modulating the effect of the MAC16 tumor. The placenta weight, but not the placental protein content, decreased only in the MAC group (Table 2 ) when compared to control. Furthermore, the fetal total protein and glucose serum levels decreased by approximately 18% and 24%, respectively, only in the MAC group (Table 2) ; these data were also affected by VIANA AND GOMES-MARCONDES diet, as the LMAC group maintained total protein and glucose levels. The chemical body composition showed that there was reduction in body fat in the MAC (approximately 53%) and A (approximately 51%) groups, in parallel with a decrease in total body protein observed only in the MAC group (41% reduction) compared with the other groups ( Table 2) .
Tumor Growth and Leucine Supplementation Altered the Fetal Serum Cytokine Profile
The fetal serum proinflammatory IL-1a cytokine levels decreased in the MAC and A groups (Fig. 1A) . IL-6 levels increased in the MAC, A, and LMAC groups (Fig. 1B) ; the L group had a decrease in IL-6 content, and the LA trended toward a decrease (P ¼ 0.055; Fig. 1B ). TNF-a content was also enhanced, but only in the LMAC group, and no change was observed in IFNc content (Fig. 1, C and D, respectively) . The groups injected with ascitic fluid mimicked all tumor growth effects in the absence of neoplastic cells; the A and LA groups exhibited changes similar to those found in the MAC and LMAC groups. Tumor growth also produced a chronic inflammatory state in the host, increasing anti-inflammatory cytokine levels, especially IL-4 and IL-10; however, in fetal serum, there were no changes in the serum levels of these antiinflammatory cytokines (Fig. 1, E and F, respectively) .
The Fetal Serum Amino Acids Profile Changed Due to Tumor Growth and Leucine Supplementation
Tumor growth affects the host by inducing a cachectic state. Therefore, to evaluate whether the maternal tumor growth jeopardizes the fetal environment, we measured the fetal serum amino acid profile. Table 3 shows the serum amino acid profile of fetuses from dams with and without tumors or ascitic fluid injections. The alanine content tended to increase in the MAC group (approximately 11% higher; P ¼ 0.08) but was significantly enhanced in the A and LMAC groups ( Fig. 2A) . A significant increase in the glutamine concentration was observed in the LMAC group compared with the respective L group, which showed a lower content compared with the C group (Fig. 2B) . Proline levels in fetal serum increased in both MAC and LMAC, as well as in A, when compared to the control group (Fig. 2C) . We found a significant increase (P , 0.005) in taurine content in both MAC and LMAC, as well as in A, groups compared to the C and L groups (Fig. 2D) . Both tumor-bearing groups presented with a tendency to increase serum serine levels (P ¼ 0.07 for MAC; P ¼ 0.06 for LMAC) when compared to C or L, respectively, (Fig. 2E) . We confirmed that the dietary supplementation increased leucine serum concentrations (L, LMAC, and LA; Fig. 2F ), and the diet accounted for 54% of total variance; therefore, the effect was considered very significant. However, the increase in the LMAC group was not as high as in the L group. In contrast, a negative correlation was found for valine and isoleucine concentrations when the animals were fed a leucine-rich diet; the concentration of these branch chain amino acids significantly decreased (valine, P , 0.005; isoleucine, P , 0.05) in all groups that received leucine supplementation (L, LMAC, and LA; Fig. 2 , G and H, and Table 3 ). However, the MAC group had a significant increase in isoleucine and tended to have elevated valine levels (P ¼ 0.06; Fig. 2 , G and H, and Table 3 ).
Tumor Growth Affected the Net Fetal Muscle Protein
The total muscle protein in fetuses from MAC mothers decreased, and the phenylalanine content tended to decrease only in the MAC fetus (P ¼ 0.062) compared with the C group (Fig. 3, A and B) . The tyrosine content in fetal muscle showed no changes in the MAC fetus compared with the C group, although the other groups had a tendency toward increased muscle tyrosine content, especially the leucine-supplemented groups (P , 0.1; Fig. 3C ). The total net muscle protein, which represents the balance between protein synthesis and degradation, was calculated as the ratio of phenylalanine and tyrosine values and was expressed as the deviation against the C group. The total net muscle protein decreased only in the MAC group compared with the other groups, especially the leucinesupplemented groups, even those from tumor-bearing dams (Fig. 3D) .
DISCUSSION
The results of the present study demonstrate that tumor growth affected the maternal host, which was reflected in fetal health. We verified changes in the fetal body composition, weight, and fetal resorption as well as in serum amino acid and cytokine profiles and total protein and glucose content, as glucose is the most important energy source for fetal growth. In a Data are expressed as the mean 6 SD. n ¼ 6 fetuses per group. C, pregnant control; MAC, tumor-bearing pregnant; A, pregnant injected with ascitic fluid (all fed with control diet; 18% protein); L, pregnant control; LMAC, tumor-bearing pregnant; LA, pregnant injected with ascitic fluid (all fed with leucine rich-diet; 18% protein þ 3% leucine). The MAC and LMAC group animals were injected with MAC16 tumors on the second day of pregnancy. The A and LA groups were injected (i.p.) daily with 0.2 ml of ascitic fluid. * P , 0.05 compared to the C group. # P , 0.05 compared to the MAC group.
TUMOR AFFECTS FETAL SERUM AND BODY COMPOSITION
addition, the net fetal muscle protein was jeopardized in fetuses from tumor-bearing mothers and was improved under leucinerich supplementation. Therefore, the leucine-rich diet supplementation could counteract some harmful effects on the fetus by improving body weight and body chemical composition, especially muscle, and some serum parameters such as amino acid and cytokine profiles. During pregnancy, fetal growth and development depend on the normal function of the placenta. This organ is responsible for the transportation of all nutrients required for fetal growth. Among these nutrients, amino acids play a crucial role because they are required for new protein formation, and also the fetal growth depends on the nutritional support provided by the placenta transport [38, 39] . Some amino acids, such as leucine, act as signaling molecules and stimulate the mTOR pathway through gene transcription and translation. It is well established that maternal food restrictions, such as protein restrictions, affect fetal growth and cause intrauterine growth restriction (IUGR), likely because protein synthesis pathways such as the mTOR pathway can be down-regulated, leading to a decrease in cell growth and activity [39] and also reducing the activity of placental amino acids transport [40] . Additionally, the fetal demand can respond differently to the changes of maternal nutritional supply, affecting the placenta transport, which has been shown to reduce activity of some amino acid transporters in IUGR [39, 40] . Tumor cells mainly use substrates such as alanine, glutamine, lactic acid, and ketone bodies for growth. Similarly, fetal growth increases the nutrient demand, emphasizing the importance of amino acids in increasing protein synthesis.
Alanine levels increase in the plasma of cancer patients because this amino acid is used as a gluconeogenic source to synthesis new glucose, which is increased in these patients [41] . On the other hand, fetal plasma concentration of amino acids could be changed under pathological condition such as IUGR [40] and also in cancer states, as found in this work. The VIANA AND GOMES-MARCONDES intense proteolysis that occurs in cancer patients is related to a higher release of alanine, which can supply the increased gluconeogenic pathway, wasting extra energy and often leading the host to a cachectic state. The protein depletion also can be due to reduced food intake-anorexia-normally found during tumor growth [42] . In accordance with these data, our results showed an increase in fetal serum alanine concentrations in the MAC and LMAC groups, suggesting the likely activation of proteolysis and gluconeogenic processes in these fetuses. Leucine-rich diet is likely to alter the system L transport across the placenta [39, 40] , which may, in turn, alter amino acid exchange across the placenta and, therefore, could be partly responsible for the maintenance of fetal weight in the LMAC group. The fluid obtained from MAC16 tumorbearing mice was injected into pregnant mice (A group) and induced effects similar to those produced by tumor growth. The tumor cells and/or host cells, in response to the tumor, produced humoral factors, mainly the proteolysis-inducing factor, which might be responsible for the alterations in the fetal amino acid profile, especially protein waste. It is well established that the amino acid profile in patients with cancer often differs from that in healthy subjects, but the influence of tumors in a pregnant mother on the fetal amino acid profile remains unclear. The tumor growth requires glutamine, glycine, aspartate, and serine for the synthesis of purine and pyrimidine and the cellular membrane. The demands of certain amino acids can lead to a gradual loss in muscular mass caused by protein degradation of host tissues and result in lower availability of amino acids, especially the essential amino acids [42] . We found significantly increased serum glutamine concentrations in the LMAC group compared with the L group; this amino acid is extensively used by the immune system and regulates protein turnover. Therefore, in these fetuses, the leucine-supplemented diet likely improved the host response and tumor damage effects. Our results also showed an increase in proline, taurine, and serine content in fetuses from the MAC and LMAC groups compared with the respective control groups (C and L). As these amino acids are normally involved in muscle and other organ functions, this increase could be related to organ development, which can be jeopardized in these fetuses. As expected, the tumor evolution led to a higher demand for alanine and glutamine, and the increased isoleucine levels in the MAC group likely provided these amino acids to the MAC fetuses for the gluconeogenesis process and for cell proliferation [43, 44] . The changes observed in other serum amino acids in fetuses from tumorbearing dams likely represented the harmful effects produced by this association between cancer and pregnancy, independent of nutritional support.
Tumor evolution leads to profound body composition changes, especially when the host is cachectic. We found that the body water ratio of fetuses from tumor-bearing mothers (MAC and LMAC) was slightly higher compared with the C group, depending on the tumor growth. This fact could in part be related to low serum proteins, verified in MAC fetuses, leading to osmoregulation dysfunction and body water retention. The literature shows that tumor evolution promotes substantial changes in the ratio of lean body mass and amount of body water [45, 46] . Consistent with the tumor evolution, there is an intense waste of fat tissue energy sources [47] . Thus, consistent with the literature, the percentage of fetal fat was reduced in the tumor-bearing MAC group but not in the LMAC group; in addition, the total protein (body and serum) was decreased only in the MAC group, suggesting the beneficial effect produced by nutritional supplementation in the LMAC fetal group. In addition, we showed that the same harmful effect produced by tumor growth could be produced by indirect actions, as the fetus from dams receiving inoculation with ascitic fluid (A) had the same decrease in fetal body fat and protein as observed in the MAC group. These results suggest that the powerful effects were a result of the indirect effect of factors produced by tumor and/or host cells-represented here by the ascitic fluid-injected group (A); these effects could be reverted by the leucine supplementation. b AABA, internal standard alpha amino butyric acid. * P , 0.05 compared to the C group. ** P , 0.005 compared to the C group. *** P , 0.001 compared to the C group. # P , 0.05 compared to the L group.
During cancer evolution, the host can develop cachexia, which comprises several physiological changes, especially a chronic inflammatory process with increases in proinflammatory cytokine content [48] [49] [50] [51] . The inflammatory cytokines related to degenerative diseases, especially cancer, are IL-6, TNF-a, IL-1b, and IFN-c [40, 41] . Thus, high levels of IL-6 in the MAC and A fetal groups indicate important changes in fetal growth and maturation, which could be related to inflammatory processes. However, despite the presence of tumors in the LMAC group, even with higher levels of IL-6 and TNF-a, these animals maintained their body weight, total body protein, and fat levels, consequently improving the total net muscle protein. These results could be related to the maintenance of serum glucose and amino acids as a powerful beneficial effect of a leucine-rich diet. Various tissue and cell types are responsible for the increase in circulating cytokines during cancer, but the tumor is the most significant source. Alone, these cytokines are capable of inducing muscle tissue depletion [51] , but this effect could be minimized in the fetal LMAC, especially in terms of maintaining the muscle tissue. TNF-a VIANA AND GOMES-MARCONDES stimulates catabolism via indirect mechanisms, alters the circulating levels of hormones that regulate muscle growth, stimulates the production of catabolic cytokines, and induces anorexia [51] . Although these effects were found in tumorbearing animals in our previous work, they were modulated with a leucine-rich diet, as verified here in the LMAC fetal group [21] [22] [23] [24] [25] . TNF-a and IL-6 are the main mediators of acute phase response by the liver during the process of cachexia. IL-6 inhibits the production of albumin in the liver, and elevated levels of cytokines are associated with high tumor size, weight loss, and poor prognosis. These processes could be extended to the MAC and A fetal groups. This cytokine has been postulated as a tumor growth factor. The cytokines IL-1b and IFN-c also mediate cachexia [52] , although here, the data showed no differences among the groups. In addition, the proinflammatory cytokines IL-6, TNF-a, IL-1b, and IL-8 act in various target cells to increase local vascularization and accelerate the inflammatory response, which could be related to the lower fetal weight, associated with placental weight reduction, found especially in the MAC group. In tissues, proteolysis occurs through the ubiquitin proteasome pathway, and activation of the ubiquitin-dependent proteases, which are in turn mediated through TNF-a, could be related to those found in fetuses from tumor-bearing mothers, which had a modulatory response under leucine-rich supplementation [53] .
Therefore, the data presented here clearly show that tumor growth had direct and indirect deleterious effects in fetuses from tumor-bearing dams (as we observed especially in the MAC group and to a lesser degree in the A group). Currently, attenuating metabolic decline in cancer is an important area of research, especially when there are two patients: mother and fetus. Further studies are underway in our laboratory to determine if and how leucine supplementation could counteract the damage to fetal growth during cancer evolution. We have previously shown the beneficial effects of a leucine-rich diet in tumor-bearing animals, and in this work, we extended these observations to certain parameters of fetal body protein and total muscle protein associated with changes in amino acid profile and serum cytokines. The present work demonstrated that leucine-rich diet interventions minimized certain deleterious effects of tumor burden on fetal health. 
